By David | Biotech News Today
Biologic medicines, such as antibodies, therapeutic proteins, vaccines, and gene therapies, make up some of the most closely watched stories in healthcare. If you follow biologics news, you will see regular headlines about new approvals, biosimilars, antibody-drug conjugates, and gene therapies. This guide explains what is happening in 2026, what the main trends mean, and where students and readers can follow reliable updates.
Note: the figures below reflect reports available through mid-2026. Regulatory news changes quickly, so always check the linked sources for the latest numbers.
What Are Biologics? A Quick Refresher
Biologics are medicines made from, or produced by, living organisms. They are usually large and complex molecules, which is why they are made in living cells and are often given by injection. If you are new to the topic, start with our guides on biopharmaceuticals and how biologic drugs are made.
Biologics News in 2026: The Big Picture
The pace of new approvals has been strong this year. BioSpace reported that the FDA approved 26 novel therapies in the first half of 2026, seven more than in the first half of 2025, with cancer and rare diseases standing out. In that analysis, small molecules led total approvals by mechanism, followed by antibodies and then peptides (BioSpace: FDA approvals in H1 2026).
A separate mid-year review noted that, through July 7, 2026, the FDA’s Center for Drug Evaluation and Research had approved 24 new drugs. About 71 percent were approved through New Drug Applications, which are mostly small molecules, and about 29 percent through Biologics License Applications (DCAT mid-year review). Vaccines, blood products, and cell and gene therapies are handled by a different FDA centre and are not included in that count.
This shows an important point for readers: biologics are a growing share of new medicines, but they are not the majority of every year’s approvals.
Key Biologics Trends to Watch
| Trend | What it means | Why it matters |
|---|---|---|
| Antibody-drug conjugates (ADCs) | An antibody linked to a drug to reach specific cells | Growing role in cancer treatment |
| Biosimilars | Follow-on versions of approved biologics | More choice and potential cost savings |
| Gene and cell therapies | Treatments that change or replace genes or cells | New options for rare and inherited diseases |
| Long-acting biologics | Products designed to be given less often | Greater convenience for patients |
| Outsourced manufacturing | Companies use contract partners | Faster and more flexible production |
Antibody-Drug Conjugates
ADCs remain a major theme. As one example, AstraZeneca’s TROP2-directed ADC Datroway received FDA approval in the first half of 2026 for first-line treatment of metastatic triple-negative breast cancer, according to the BioSpace review above. To learn how these products are developed, read our guide on biologics development and outsourcing.
Biosimilars
BioWorld reported that the FDA approved three biosimilar products from Samsung Bioepis and Formycon on June 28, 2026. They are follow-on versions of Stelara (ustekinumab), Neupogen (filgrastim), and Eylea (aflibercept) (BioWorld). A biosimilar is not a copy in the way a generic tablet is, because living cells make biologics and no two products can be exactly identical.
Long-Acting Insulin
The DCAT review also highlighted the March 2026 approval of Awiqli (insulin icodec), described as the first FDA-approved once-weekly basal insulin for adults with type 2 diabetes. Insulin is a classic biologic, so this is a clear example of how older biologic categories continue to evolve.
Gene Therapy and Blood Products
RTTNews reported that on July 1 the FDA approved Vertex’s Casgevy as the first gene therapy for young children with sickle cell disease. It also reported that on July 29 the FDA licensed Ezplaz Freeze-Dried Plasma, the first freeze-dried plasma product approved for use in the United States (RTTNews via Nasdaq). Both are handled as biologics rather than traditional drugs.
What Is Driving These Trends?
Several forces are behind the headlines:
- Better science. Advances in antibody engineering, gene editing, and protein design make new products possible.
- Patient need. Many serious and rare diseases have few treatment options, which pushes developers toward biologics.
- Competition after patent expiry. Biosimilars bring new manufacturers into established markets.
- Manufacturing partnerships. Many sponsors rely on contract partners; see our explainer on what a CDMO is.
- Process improvements. Better process control helps companies produce consistent products at scale. Learn more in our guide to process development and control.
How to Read Biologics News Carefully
Headlines can be exciting, but they do not always give the full story. These habits will help you read them with a clear mind:
- Check the stage. Early lab results, clinical trial results, and an actual approval are very different milestones.
- Look for the source. Prefer regulators, company filings, peer-reviewed journals, and established trade publications.
- Separate approval from availability. An approved product may take time to reach patients or may be limited to certain groups.
- Watch the wording on claims. Terms such as “first,” “breakthrough,” or “cure” should be backed by clear evidence.
- Remember the audience. News written for investors may focus on stock prices rather than patient benefit.
Where to Follow Reliable Biologics News
| Source type | Examples | Best for |
|---|---|---|
| Regulators | FDA, EMA | Official approvals and safety information |
| Trade news | BioSpace, BioWorld | Industry and company developments |
| Scientific journals | Peer-reviewed biotechnology and medicine journals | Detailed research results |
| Company announcements | Press releases and filings | First-hand product updates |
The FDA’s Center for Biologics Evaluation and Research keeps a running list of recent approval letters and updates on its What’s New for Biologics page. It is a useful place to confirm news about vaccines, gene therapies, and blood products directly from the regulator.
For background on how the wider industry fits together, see our article on biotech vs pharma.
Why Biologics News Matters for Students
Following the news is a practical way to connect classroom topics to real events. When you read about a new approval, ask yourself: What type of molecule is it? How is it made? Who might manufacture it? What problem does it solve? Questions like these turn headlines into learning and can also help you spot career areas, from research and process development to regulatory affairs and quality.
Frequently Asked Questions
What are biologics? Biologics are medicines made from, or produced by, living organisms, such as antibodies, vaccines, and gene therapies.
How many new drugs does the FDA approve each year? Numbers vary by year. Reports cited above note 46 new drug approvals by CDER for full-year 2025 and 24 through early July 2026.
Are biosimilars the same as generics? No. A generic is an identical copy of a chemical drug, while a biosimilar is highly similar to an approved biologic but not identical.
What is an antibody-drug conjugate? It is an antibody linked to a drug so the drug can be delivered to specific cells.
Where can I check official biologics approvals? The FDA’s CBER website and the FDA’s drug approval pages list official approvals and updates.
Final Thoughts
Biologics news in 2026 points to steady growth in antibodies, ADCs, biosimilars, and gene therapies, alongside a strong overall pace of FDA approvals. The best way to follow the field is to focus on trusted sources, check the stage of each claim, and connect each story to the science behind it. We will keep covering these developments here on Biotech News Today.
This article is for educational purposes only and is not medical or investment advice.
Leave a Reply